Cambridge Cognition Holdings


Cambridge Cognition develops and commercialises computerised neuropsychological tests for sale worldwide, principally in the UK, the US and Europe.  They deliver near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders. 

For over 30 years their CANTAB® technology has advanced the assessment of cognition in global scientific research; clinical trials; and clinical practice, accelerating the development of safe and effective treatments, improving patient outcomes and to helping assess, monitor and manage cognitive health throughout life. 

The Company has three main business units catering for the academic research, pharmaceutical development and healthcare technology markets.